Lapinsky S E, Mullen J B, Balter M S
Department of Medicine, Mount Sinai Hospital, Toronto, Ontario.
Can J Cardiol. 1993 May;9(4):322-4.
Amiodarone causes accumulation of phospholipids in lung alveolar cells, and this phospholipidosis invariably is present when amiodarone pulmonary toxicity is recognized. This effect has usually been demonstrated in patients following several months of therapy. The authors report the occurrence of pulmonary phospholipidosis, diagnosed by bronchoalveolar lavage, six days after commencing intravenous amiodarone therapy.
